Doctors Warn White Coat Hypertension May Quietly Raise Heart Disease Risk
Introduction
The term white coat hypertension has long been used in clinical practice. It describes a condition in which a patient consistently shows elevated blood pressure readings in a doctor’s office while maintaining normal blood pressure levels at home (1). Individuals diagnosed with white coat hypertension differ from patients with persistent arterial hypertension not only in terms of blood pressure values measured at home and in clinical settings. Research has shown that white coat hypertension is more common in women and younger individuals, and these patients are less likely to be obese.
Different studies report varying prevalence rates of white coat hypertension. These differences are influenced by demographic and clinical characteristics, varying definitions of normal home blood pressure ranges, differences in measurement techniques, and other methodological factors. Nevertheless, most experts agree that white coat hypertension is a common condition, diagnosed in approximately 25–30% of patients attending outpatient hypertension clinics (2). An analysis of data from the Spanish Ambulatory Pressure Monitoring Registry found that white coat hypertension was present in about one-quarter of patients who were not taking blood pressure medication (3).
The importance of blood pressure measurement methods in diagnosing white coat hypertension is further supported by findings from the epidemiological PAMELA (Pressioni Arteriose Monitorate E Loro Associazioni) study. Conducted by Italian researchers, the PAMELA study aimed to establish normal ranges for ambulatory and home blood pressure in the general population. When only home blood pressure readings were evaluated, white coat hypertension was identified in 9% of participants. Using 24-hour ambulatory blood pressure monitoring, the condition was diagnosed in 12% of study participants (4).
The growing body of scientific evidence no longer allows white coat hypertension to be viewed as a harmless or insignificant clinical feature. Increasing research suggests that this condition may play an important role in raising the risk of cardiovascular disease.
This article provides a more detailed overview of the risks associated with white coat hypertension and presents a modern perspective on this common yet frequently underestimated condition.
Increased Risk of Hypertension
Individuals diagnosed with white coat hypertension have a significantly higher risk of developing primary hypertension over time. In the PAMELA study, participants were classified as having white coat hypertension based on blood pressure measurements taken both at home and in the doctor’s office. Long-term follow-up showed that individuals with white coat hypertension had a 2.5-times higher risk of developing sustained hypertension over a 10-year period when elevated blood pressure readings were observed both in clinical settings and at home. This increased risk was independent of age and sex (5).
More recently, the risk of progression from white coat hypertension to persistent hypertension was evaluated in Finland through a nationwide population study with an 11-year follow-up period (6). The results showed that 18% of individuals with normal blood pressure both at home and in clinical settings developed sustained hypertension during follow-up. In contrast, 52% of participants diagnosed with white coat hypertension developed persistent hypertension over the same period.
These findings suggest that individuals with white coat hypertension have nearly a threefold higher risk of developing sustained hypertension compared with people without this condition.
Risk of Metabolic Disorders
In recent years, researchers have accumulated substantial evidence linking white coat hypertension to other cardiovascular diseases. Individuals diagnosed with white coat hypertension tend to have higher levels of cholesterol, triglycerides, uric acid, and glucose in the blood, as well as a larger waist circumference and higher body mass index. They are also more likely to be diagnosed with metabolic syndrome (7).
These metabolic disturbances interact with elevated blood pressure and may contribute to target organ damage. The heart, blood vessels, and kidneys can all be affected by these processes. Disturbances in glucose metabolism appear to play a particularly important role within this chain of risk factors.
Studies have shown that patients with white coat hypertension are significantly more likely to develop diabetes, and impaired glucose tolerance is diagnosed more frequently in this group. Disorders of glucose metabolism are themselves independent risk factors for cardiovascular disease. Conclusions from the PAMELA study further emphasize that a diagnosis of white coat hypertension significantly increases the risk of developing diabetes over a 10-year period. Moreover, the authors noted that this risk is comparable to that observed in individuals with primary hypertension (4, 5, 7).
Organ Damage
An increasing amount of evidence points to subclinical target organ damage caused by white coat hypertension. Today, white coat hypertension is considered an intermediate state between normal blood pressure and sustained hypertension in terms of target organ involvement.
Recent meta-analyses have demonstrated progressive morphological and functional changes in the heart among patients with white coat hypertension. These changes include an increase in left ventricular mass index, impaired diastolic function reflected by altered early and late left ventricular filling through the mitral valve, and enlargement of the left atrium.
Target organ damage in white coat hypertension is not limited to the heart. The entire vascular system may be affected. Studies have shown that arteries supplying the brain can undergo structural changes, including thickening of the intima-media layer of the common carotid artery.
From a pathophysiological perspective, white coat hypertension resembles an intermediate condition between normal blood pressure and sustained hypertension, characterized by specific structural changes in the cardiovascular system.
Less is known about the effects of white coat hypertension on large artery stiffness, subclinical kidney injury, and retinal damage. However, some authors have linked white coat hypertension to increased pulse wave velocity, microalbuminuria, which is considered an early sign of kidney damage, and even retinopathy.
Risk of Cardiovascular Diseases
Numerous scientific studies and meta-analyses have associated white coat hypertension with an increased risk of cardiovascular disease and related complications.
Earlier studies attempting to establish the relationship between white coat hypertension and cardiovascular disease incorrectly suggested that cardiovascular morbidity and mortality rates in these patients were similar to those observed in healthy individuals. However, more detailed research and subsequent meta-analyses have demonstrated that the cardiovascular risk associated with white coat hypertension is intermediate — significantly higher than in healthy individuals, but lower than in patients with sustained hypertension.
This conclusion was supported by the prospective clinical study IDHOCO (International Database of Home Blood Pressure in Relation to Cardiovascular Outcomes). The study collected data from 6,458 individuals across five countries. Results from the eight-year follow-up demonstrated that white coat hypertension significantly increases the risk of cardiovascular disease.
Participants in the PAMELA clinical trial were followed for 16 years. Researchers evaluated mortality rates among patients diagnosed with white coat hypertension. The findings revealed that participants whose elevated blood pressure was not detected at every office visit had a mortality risk similar to individuals with normal blood pressure. In contrast, participants whose blood pressure remained elevated during all doctor visits had a significantly higher mortality risk.
The PAMELA study provides important evidence supporting the impact of white coat hypertension on long-term prognosis.
Treatment Options
At present, there are no large randomized clinical trials demonstrating the benefits of treating white coat hypertension with blood pressure-lowering medications.
However, the 2013 guidelines of the European Society of Hypertension and the European Society of Cardiology on the diagnosis and treatment of arterial hypertension emphasize that treatment decisions should be individualized. Physicians are encouraged to assess the patient’s overall cardiovascular risk profile, existing risk factors, target organ damage, general health status, and chronic diseases before deciding on therapy.
For patients with white coat hypertension who do not have additional cardiovascular risk factors, pharmacological treatment is generally not recommended. In these cases, lifestyle modification is considered essential. Recommended measures include increasing physical activity, reducing body weight, limiting salt intake, quitting smoking, and avoiding other harmful habits.
It is important to remember that these patients still carry an elevated cardiovascular risk. Long-term follow-up is therefore recommended. Patients should regularly monitor blood pressure at home and attend follow-up visits where physical examinations, laboratory and instrumental tests, and office blood pressure measurements are performed. These measures help ensure the timely diagnosis of sustained hypertension and the prevention of cardiovascular complications.
In some cases, patients with white coat hypertension may also have a high or very high cardiovascular risk, type 2 diabetes, chronic kidney disease, or evidence of target organ damage. In such situations, the potential benefit of pharmacological treatment should be considered, as lifestyle modifications alone may not be sufficient.
Conclusion
This article reviewed recent scientific evidence highlighting the clinical importance of white coat hypertension. White coat hypertension is not a harmless or insignificant condition. On the contrary, it is associated with metabolic disturbances, target organ damage, and an increased risk of cardiovascular disease.
When evaluating and managing patients with white coat hypertension, careful assessment of cardiovascular risk factors and target organ damage is essential.
Although there are currently no evidence-based treatment recommendations specifically for white coat hypertension, the 2013 guidelines of the European Society of Hypertension and the European Society of Cardiology suggest that pharmacological treatment may provide benefits for patients with high or very high cardiovascular risk.
Future randomized clinical trials evaluating morbidity and mortality outcomes are needed to answer the remaining questions regarding the benefits of treating white coat hypertension.
Publication "Internist" No. 1 2018.
Prepared according to Grassi G. White-coat hypertension: not so innocent. E-Journal of Cardiology Practice. Oct. 2016;Vol. 14:No. 26–21.
